Brickell Biotech Inc

NASDAQ:BBI  
0.66
+0.01 (+0.79%)
Other Pre-Announcement

Brickell Biotech Reports Q3 Revenue Of $100,000

Published: 11/12/2020 21:11 GMT
Brickell Biotech Inc (BBI) - Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Q3 Revenue $100,000 Versus $1.2 Million.
Planned Commercial Launch of Ecclock in Japan by Development Partner, Kaken, Expected by End of 2020.
Brickell Biotech - Recently Completed Capital Raise Expected to Fully Fund U.S. Pivotal Phase 3 Program, With Topline Results Anticipated in Q4 2021.
Brickell Biotech - on Track to Initiate Cardigan Ii Study, Second U.S. Pivotal Phase 3 Clinical Study, Later This Year.
Brickell Biotech - Qtrly Net Loss per Common Share Attributable to Common Stockholders$0.15.